E. Castanon Álvarez

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Juanita Lopez, S. Im, H. Chung, 2021, Journal of Clinical Oncology.

3D waterfall plots: a better graphical representation of tumor response in oncology.

J. Soria, S. Aspeslagh, E. Castanon Álvarez, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy.

G. Bastarrika Alemán, A. Ezponda Casajús, E. Castanon Álvarez, 2019 .

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Juanita Lopez, S. Im, H. Chung, 2022, Journal of Clinical Oncology.

MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

S. Ou, A. Joe, H. Prenen, 2022, European Journal of Cancer.

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Juanita Lopez, H. Chung, A. Hendifar, 2022, Journal of Clinical Oncology.

Abstract CT014: Efficacy of intratumoral BO-112 with systemic pembrolizumab in patients with advanced melanoma refractory to anti-PD-1-based therapy: Final results of SPOTLIGHT203 phase 2 study

A. Arance, Helena Escuin-Ordinas, S. Dalle, 2022, Cancer Research.

Safety and clinical activity of oleclumab (O) ± durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A phase 1b/2 randomized study.

N. Pavlakis, A. Nagrial, M. Overman, 2023, Journal of Clinical Oncology.

Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.

K. Hoang-Xuan, M. Sanson, A. Idbaih, 2022, European Journal of Cancer.